Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma Review
| Authors: | Abramson, J. S.; Stuver, R.; Herrera, A.; Patterson, E.; Wen, Y. P.; Moskowitz, A. |
| Review Title: | Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma |
| Abstract: | The ECHELON-1 trial demonstrated the effectiveness of brentuximab vedotin (BV) in combination with doxorubicin, vinblastine, and dacarbazine as a frontline treatment regimen in classical Hodgkin lymphoma. However, peripheral neuropathy (PN) is common with this regimen, occurring in up to two-thirds of patients. While standard prescribing information recommends BV dose modification at the onset of grade 2 PN, management strategies for PN are not well-defined. Most commonly, clinicians dose reduce or discontinue BV, vinblastine, or both. We review evidence-based and practical approaches for managing peripheral neuropathy, emphasizing early detection and dose modification. © 2024 The Authors |
| Keywords: | adult; major clinical study; review; doxorubicin; drug dose reduction; side effect; drug megadose; dacarbazine; multiple cycle treatment; peripheral neuropathy; vinblastine; drug combination; drug therapy; adverse drug reaction; therapy; oral drug administration; classical hodgkin lymphoma; drug comparison; brentuximab vedotin; dose modification; human; female |
| Journal Title: | Critical Reviews in Oncology/Hematology |
| Volume: | 204 |
| ISSN: | 1040-8428 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2024-12-01 |
| Start Page: | 104499 |
| Language: | English |
| DOI: | 10.1016/j.critrevonc.2024.104499 |
| PUBMED: | 39244180 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work